Anais Schavgoulidze

Toulouse, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.

PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.

Journal: Blood
Published: February 25, 2026

Atypical mast cells and multiple myeloma: An ambiguous alliance with diagnostic implications.

Atypical mast cells and multiple myeloma: An ambiguous alliance with diagnostic implications.

Journal: British journal of haematology
Published: February 16, 2026

t(11;14) multiple myeloma patient: minimal residual disease after 10 years of follow-up - a case report.

t(11;14) multiple myeloma patient: minimal residual disease after 10 years of follow-up - a case report.

Journal: Haematologica
Published: August 14, 2025

Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study.

Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study.

Journal: Blood cancer journal
Published: June 07, 2025

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.

Journal: Blood
Published: May 15, 2025

DIS3 licenses B cells for plasma cell differentiation in humans.

DIS3 licenses B cells for plasma cell differentiation in humans.

Journal: Cellular & molecular immunology
Published: February 12, 2025

ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.

ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.

Journal: Blood cancer discovery
Published: February 03, 2025

Fishing for 1q gain is now open in amyloidosis.

Fishing for 1q gain is now open in amyloidosis.

Journal: Blood
Published: December 19, 2024

CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.

CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.

Journal: Blood cancer journal
Published: June 14, 2024

RAS/RAF landscape in monoclonal plasma cell conditions.

RAS/RAF landscape in monoclonal plasma cell conditions.

Journal: Blood
Published: August 22, 2023

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.

Journal: Blood cancer journal
Published: August 21, 2023

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 07, 2022
Showing 1-12 of 23

Last Updated: 09/26/2026